By Ben GlickmanShares of Arcutis Biotherapeutics rose late Friday after the company's treatment for a skin condition was approved by the Food and Drug Administration. Zoryve topical foam has been approved for the treatment of seborrheic dermatitis, a skin condition which mostly affects the scalp, the Westlake Village, Calif.-based dermatology company said. A cream form of Zoryve was already approved by the FDA for the topical treatment of plaque psoriasis in patients 6 years of age and older. Arcutis said it plans to make the topical foam widely available by the end of next month. Write to Ben Glickman at ben.glickman@wsj.com(END) Dow Jones NewswiresDecember 15, 2023 17:58 ET (22:58 GMT)Copyright (c) 2023 Dow Jones & Company, Inc.

Source: Wall Street Journal December 15, 2023 23:07 UTC